Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance
M Yang, C Lin, Y Wang, K Chen, H Zhang, W Li - Genome Medicine, 2022 - Springer
Background Immune checkpoint blockade (ICB) therapy has revolutionized the treatment of
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with …
lung squamous cell carcinoma (LUSC). However, a significant proportion of patients with …
Single-cell RNA sequencing reveals the heterogeneity of tumor-associated macrophage in non-small cell lung cancer and differences between sexes
Non-Small Cell Lung Cancer (NSCLC) is a disease with high morbidity and mortality, which
has sex-related differences in prognosis and immunotherapy efficacy. However, the …
has sex-related differences in prognosis and immunotherapy efficacy. However, the …
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
Immunotherapy is a mainstay of non-small cell lung cancer (NSCLC) management. While
tumor mutational burden (TMB) correlates with response to immunotherapy, little is known …
tumor mutational burden (TMB) correlates with response to immunotherapy, little is known …
[HTML][HTML] Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context
M Wiesweg, F Mairinger, H Reis, M Goetz… - European Journal of …, 2020 - Elsevier
Objective Current predictive biomarkers for PD-1 (programmed cell death protein 1)/PD-L1
(programmed death-ligand 1)-directed immunotherapy in non-small cell lung cancer …
(programmed death-ligand 1)-directed immunotherapy in non-small cell lung cancer …
[HTML][HTML] Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
PH Lizotte, EV Ivanova, MM Awad, RE Jones, L Keogh… - JCI insight, 2016 - ncbi.nlm.nih.gov
BACKGROUND. Immune checkpoint blockade improves survival in a subset of patients with
non–small-cell lung cancer (NSCLC), but robust biomarkers that predict response to PD-1 …
non–small-cell lung cancer (NSCLC), but robust biomarkers that predict response to PD-1 …
[HTML][HTML] Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC
Introduction The combination of programmed cell death protein-1 or programmed death-
ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment …
ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment …
Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor
Characterizing the molecular immune subtype and micro-environment of lung cancer is
necessary to understand immunogenic interactions between infiltrating immune and stromal …
necessary to understand immunogenic interactions between infiltrating immune and stromal …
Integrating Single-cell RNA-seq to construct a Neutrophil prognostic model for predicting immune responses in non-small cell lung cancer
J Pang, Q Yu, Y Chen, H Yuan, M Sheng… - Journal of translational …, 2022 - Springer
Non-small cell lung cancer (NSCLC) is the most widely distributed tumor in the world, and its
immunotherapy is not practical. Neutrophil is one of a tumor's most abundant immune cell …
immunotherapy is not practical. Neutrophil is one of a tumor's most abundant immune cell …
The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery
ÅK Öjlert, AR Halvorsen, D Nebdal… - Molecular …, 2019 - Wiley Online Library
The impact of the tumor immune microenvironment on overall survival in non‐small cell lung
cancer (NSCLC) has been studied, but there is little information on its relevance for risk of …
cancer (NSCLC) has been studied, but there is little information on its relevance for risk of …
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
S Wang, P Yuan, B Mao, N Li, J Ying, X Tao… - npj Precision …, 2022 - nature.com
Several clinical trials have shown the safety and effectiveness of PD-1/PD-L1 inhibitors in
neoadjuvant therapy in resectable non-small cell lung cancer (NSCLC). However, 18–83 …
neoadjuvant therapy in resectable non-small cell lung cancer (NSCLC). However, 18–83 …